LY3022855
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for LY3022855, covering 2023-10-16 to 2024-10-28. Get the full timeline:
Most recent: Clinical Trial Update: A Study of LY3022855 In Participants With Breast or Prostate Cancer [Phase 1]